微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 86.55% | -0.85% | 0.25% | 12/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 86.33% | -0.52% | 0.62% | 11/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 85.8% | 0.18% | -1.51% | 12/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 87.12% | 0.48% | -0.2% | 12/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 87.29% | -0.33% | 0.59% | 10/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 86.78% | -1.29% | 1.32% | 9/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 85.64% | -3.36% | -1.22% | 10/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 86.71% | -2.71% | -0.99% | 10/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 87.58% | -2.69% | -0.39% | 9/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 87.91% | -2.86% | -0.8% | 9/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 88.63% | -3.62% | -0.56% | 8/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 89.12% | -5.53% | -0.97% | 8/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 89.99% | -3.94% | -0.56% | 8/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 90.5% | -3.38% | -1.57% | 7/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 91.95% | -1.32% | -2.53% | 6/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 94.34% | -0.68% | 0.7% | 4/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 93.68% | -1.7% | 0.02% | 3/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 93.67% | -1.69% | 0.52% | 3/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 93.18% | -1.76% | -1.9% | 4/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 94.99% | -0.01% | -0.34% | 4/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 95.31% | 0.23% | 0.03% | 3/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 95.28% | 0.15% | 0.45% | 2/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 94.85% | 1.49% | -0.15% | 2/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 95% | -0.84% | -0.09% | 3/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 95.09% | -1.04% | -0.05% | 3/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 95.14% | -1.02% | 1.79% | 1/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 93.46% | -2.14% | -2.45% | 2/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 95.81% | -0.48% | -0.29% | 1/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 96.09% | 2% | -0.03% | 1/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 96.11% | 2% | 0.64% | 1/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 95.5% | 2% | -0.8% | 1/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 96.27% | 1.08% | 1.08% | 1/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2017-12-31 | 95.24% | -2.28% | -2.28% | 2/159 | 52.25% | 贝达药业 | 95.47% | 行业排名> |
| 2016-12-31 | 97.46% | 2% | 2% | 1/159 | 48.17% | 贝达药业 | 95.51% | 行业排名> |